Alexion Pharmaceuticals Buys Enobia Pharma

Alexion Pharmaceuticals Inc. will pay $610 million in cash – and as much as $470 million in future milestone-based payments - to acquire Enobia Pharma Corp. Enobia is a biopharma company developing therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders. Enobia closed a $40 million round earlier this year, and was backed by investors including OrbiMed Advisors, CTI Life Sciences Fund, Desjardins Venture Capital and Lothian Partners.

DealsNorth AmericaUSBriefs